Andrew Dudum: Yes, it’s a great question. We haven’t disclosed anything specific on that. I think the best guidance I could probably give you is — probably point to the personalization adoption. We’ve gone essentially zero to north of 30% of subscribers on the platform being treated with the personalized offering and the newer categories like dermatology and weight loss between 70% and 100% personalized. I would say that those personalized solutions for the most part, often include expanded value. They might include mobile dual action or triple action or supplement that counter some type of side effect or a concern of the patient or multiple dosages or custom dosages. And so I think the rapid adoption of personalized treatment is a really exciting indicator for us of the commitment to the platform and the recommitment of this platform for patients that are in many situations, upselling and adopting the new offerings that are coming on to the platform at a very, very vast market affordable prices.
Ivan Feinseth: Thanks and looking forward to a big 2024 for you.
Andrew Dudum: Thanks, Ivan.
Operator: Your next question comes from the line of Michael Cherny from Leerink Partners. Please go ahead.
Michael Cherny: Good afternoon, evening, guys, and thank you for the question. A lot of mine have been addressed, but I guess I just want to harp a little bit more on the gross margin side. It’s great that you have the operating leverage to drive towards the long-term margins as you outlined, Yemi. But why is that level kind of mid- to high-70s the kind of right number in terms of the way you see pricing and tie back towards customer benefits? Just trying to understand how that fits into the broader scaling effect. And as you settle on that number, whether you’re on the pathway there or before you get there, why landing in that number is the right level? And is there a potential variability to the upside or the downside beyond that?
Yemi Okupe: Yes. Thanks, Michael. I think it’s a great question. So the teams, you spend a lot of time running scenarios on like what we call as our North Star, which is effectively across a variety of different improvements to our model as well as give back to consumers, where do we think that optimal equilibrium lens. And so what we do see is, as Andrew mentioned, given the fact that we’re not looking to add another 500,000 or 1 million subscribers, we’re looking to eventually bring on tens of million subscribers onto the platform, placing our offerings or having a segmented offering that’s at different price points for different users is something that is fundamentally important to us. And so as we’ve started to run different scenarios, we view that we can offer that holistic suite both at the premium and the mid-end and the mass market and at a margin profile that lands in the mid-70s, like as mentioned previously, that will take some time.
I think you’ll see periods where margins similar to like last year may actually expand as we unlock efficiencies in advance of that. But over time, like we view the pathway to get to tens of millions of subscribers, having a mass market offering as well as a critical element to that.
Michael Cherny: Cool. That’s it for me. Thanks so much.
Operator: We have no further questions in our queue at this time. And that does conclude today’s conference call. Thank you for your participation. And you may now disconnect.
